Immunome Inc.

For the period ended Dec 31, 2025. Filed Mar 3, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 3, 2026

IMNM$19.36+3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Cover page Table of Contents

PART I

Item 1. Business (no text here)

Item 1. Business Item 1A. Risk Factors

Item 1B. Unresolved Staff Comments (no text here)

Item 1B. Unresolved Staff Comments

Item 1C. Cybersecurity (no text here)

Item 1C. Cybersecurity

Item 2. Properties (no text here)

Item 2. Properties

Item 3. Legal Proceedings (no text here)

Item 3. Legal Proceedings

Item 4. Mine Safety Disclosures (no text here)

Item 4. Mine Safety Disclosures

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities (no text here)

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information Holders Dividends

Item 6. [Reserved] (no text here)

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations (no text here)

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 7A. Quantitative and Qualitative Disclosures About Market Risk (no text here)

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

Item 8. Financial Statements and Supplementary Data (no text here)

Item 8. Financial Statements and Supplementary Data

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure (no text here)

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9A. Controls and Procedures (no text here)

Item 9A. Controls and Procedures

Item 9B. Other Information (no text here)

Item 9B. Other Information

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections (no text here)

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

PART III

Item 10. Directors, Executive Officers and Corporate Governance (no text here)

Item 10. Directors, Executive Officers, and Corporate Governance

Item 11. Executive Compensation (no text here)

Item 11. Executive Compensation

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters (no text here)

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 13. Certain Relationships and Related Transactions, and Director Independence (no text here)

Item 13. Certain Relationships and Related Transactions, and Director Independence

Item 14. Principal Accountant Fees and Services (no text here)

Item 14. Principal Accountant Fees and Services

PART IV

Item 15. Exhibits and Financial Statement Schedules (no text here)

Item 15. Exhibits and Financial Statement Schedules Management contracts or compensatory plans or arrangements Item 16. Form 10-K Summary Power of Attorney (included on the Signatures page of this Annual Report on Form 10-K)Financial Statements Item 8. Report of Independent Registered Public Accounting Firm Consolidated Balance Sheets as of December 31, 2025 and 2024 Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2025 and 2024 Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2025 and 2024 Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024 Notes to the Consolidated Financial Statements 1. Nature of the business 2. Summary of significant accounting policies 3. Fair value measurement 4. Collaboration agreement with AbbVie 5. Balance sheet components 6. Employee benefit plan 7. Strategic transactions and agreements 8. Leases 9. Common stock 10. Share-based compensation 11. Segment information 12. Income taxes

Item 2. Properties

We currently lease approximately 53,000 square feet of office and laboratory space in Bothell, Washington under a lease that expires on March 31, 2033. We believe our leased space is sufficient to meet our immediate facility needs, and that any additional space we may require will be available on commercially reasonable terms.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.